New breast cancer treatment cuts the risk of recurrence in patients by 25% - Daily Mail

[unable to retrieve full-text content]

1. New breast cancer treatment cuts the risk of recurrence in patients by 25%  Daily Mail
2. Dr. Johnston on the Results of monarchE With Abemaciclib in High-Risk Early Breast Cancer  OncLive
3. First new drug in years reduces recurrence in high risk HR+ early breast cancer  Medical Xpress
4. Abemaciclib Doublet Demonstrates OS Benefit in HR+, HER2- Metastatic Breast Cancer  Targeted Oncology
5. ESMO: Lilly's Verzenio pressures Pfizer with practice-changing win in early breast cancer  FiercePharma
6. View Full coverage on Google News

https://news.google.com/__i/rss/rd/articles/CBMicmh0dHBzOi8vd3d3LmRhaWx5bWFpbC5jby51ay9uZXdzL2FydGljbGUtODc1MzMwNy9OZXctYnJlYXN0LWNhbmNlci10cmVhdG1lbnQtY3V0cy1yaXNrLXJlY3VycmVuY2UtcGF0aWVudHMtMjUuaHRtbNIBdmh0dHBzOi8vd3d3LmRhaWx5bWFpbC5jby51ay9uZXdzL2FydGljbGUtODc1MzMwNy9hbXAvTmV3LWJyZWFzdC1jYW5jZXItdHJlYXRtZW50LWN1dHMtcmlzay1yZWN1cnJlbmNlLXBhdGllbnRzLTI1Lmh0bWw?oc=5

2020-09-20 19:08:48Z
52781071540646